DC-SIGN as an attachment factor mediates Japanese encephalitis virus infection of human dendritic cells via interaction with a single high-mannose residue of viral E glycoprotein  by Wang, Ping et al.
Virology 488 (2016) 108–119Contents lists available at ScienceDirectVirologyhttp://d
0042-68
n Corr
itute o
Fax: þ8
E-mjournal homepage: www.elsevier.com/locate/yviroDC-SIGN as an attachment factor mediates Japanese encephalitis virus
infection of human dendritic cells via interaction with a single
high-mannose residue of viral E glycoprotein
Ping Wang a,b, Kai Hu a, Sukun Luo a,b, Mudan Zhang a,b, Xu Deng a,b, Chang Li a,b, Wei Jin a,b,
Bodan Hu a,b, Siyi He a,b, Mei Li a,b, Tao Du a, Gengfu Xiao a, Bo Zhang a, Yalan Liu a,
Qinxue Hu a,c,n
a State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
b University of Chinese Academy of Sciences, Beijing 100049, China
c Institute for Infection and Immunity, St George's University of London, London SW17 0RE, UKa r t i c l e i n f o
Article history:
Received 10 August 2015
Returned to author for revisions
6 November 2015
Accepted 9 November 2015
Available online 26 November 2015
Keywords:
Japanese encephalitis virus
Dendritic cell
Attachment factor
DC-SIGN
Glycoprotein
Internalizationx.doi.org/10.1016/j.virol.2015.11.006
22/& 2015 Elsevier Inc. All rights reserved.
esponding author at: State Key Laborator
f Virology, Chinese Academy of Science
6 2787199992.
ail address: qhu@wh.iov.cn (Q. Hu).a b s t r a c t
The skin-resident dendritic cells (DCs) are thought to be the ﬁrst defender to encounter incoming viruses
and likely play a role in Japanese encephalitis virus (JEV) early infection. In the current study, following
the demonstration of JEV productive infection in DCs, we revealed that the interaction between JEV
envelope glycoprotein (E glycoprotein) and DC-SIGN was important for such infection as evidenced by
antibody neutralization and siRNA knockdown experiments. Moreover, the high-mannose N-linked
glycan at N154 of E glycoprotein was shown to be crucial for JEV binding to DC-SIGN and subsequent
internalization, while mutation of DC-SIGN internalization motif did not affect JEV uptake and inter-
nalization. These data together suggest that DC-SIGN functions as an attachment factor rather than an
entry receptor for JEV. Our ﬁndings highlight the potential signiﬁcance of DC-SIGN in JEV early infection,
providing a basis for further understanding how JEV exploits DC-SIGN to gain access to dendritic cells.
& 2015 Elsevier Inc. All rights reserved.Introduction
Japanese encephalitis virus (JEV) is an enveloped single-
stranded positive-sense RNA virus belonging to the genus Flavi-
virus. JEV is arthropod-borne and maintained in a zoonotic cycle
between mosquitoes and pigs or wild birds, and could also be
transmitted to humans and horses (Lopez et al., 2015; van den
Hurk et al., 2009). According to statistics from the World Health
Organization, despite the existence of JEV vaccines, Japanese
encephalitis (JE) is still the main cause of viral encephalitis in
many countries of Asia with nearly 68,000 clinical cases every
year. There is no cure for the disease. Currently, treatment is
focused on relieving severe clinical signs by supporting the
patients to overcome the infection. Although symptomatic JE is
rare, the case-fatality rate can be as high as 30%. Permanent
neurological or psychiatric sequelae can occur in 30–50% of those
with encephalitis (Lopez et al., 2015). It is believed that a more
comprehensive understanding of JEV early infection may offery of Virology, Wuhan Inst
s, Wuhan 430071, China.approaches for the development of novel antiviral drugs and other
intervention measures.
The entry of JEV into target cells is mediated by the interactions
between the viral envelope glycoprotein E and cellular receptor(s).
JEV can replicate in various types of primary cells and immorta-
lized cell lines from a wide variety of avian, mammalian, amphi-
bian and insect species, suggesting that multiple receptors are
likely to be involved in JEV entry (Pierson and Kielian, 2013). To
date, a number of cell molecules have been proposed as JEV can-
didate receptors in different cell types. For instance, heparan sul-
fate and low-density lipoprotein receptors, as low-afﬁnity attach-
ment factors that concentrate the viral particles on the cell surface,
can be utilized by several ﬂaviviruses including JEV (Albecka et al.,
2012; Chen et al., 1997; Chien et al., 2008; Jiang et al., 2012; Lee et
al., 2006). Integrin αVβ3 has been shown to function as a primary
receptor on mammalian cells for West Nile virus and JEV (Chu and
Ng, 2004b); however, other studies indicate that αVβ3 is not
required for viral entry in some cellular context (Medigeshi et al.,
2008). HSP70 has also been suggested to serve as the putative
receptor for JEV in mouse neuroblastoma cells (Das et al., 2009;
Zhu et al., 2012). Nevertheless, receptor(s) that JEV utilizes to entry
and/or attach to target cells remains inconclusive.
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that can capture microorganisms in the peripheral mucosal tissues
and then migrate to secondary lymphoid organs, where they
present microorganisms in antigenic form to resting T cells and
thus initiate adaptive immune responses (Malissen et al., 2014).
Recent studies suggest that DCs, which are normal residents of the
skin, represent an early target for ﬂaviviruses. Infected DCs
migrate to draining lymph nodes, where efﬁcient viral replication
takes place and subsequently leads to viremic stage with virus
entry of circulation and internal organs (Diamond et al., 2003;
Pierson and Kielian, 2013), suggesting the potential importance of
DCs in JEV primary infection and transmission. Understanding the
signiﬁcance of DCs in JEV early infection is critical not only for
elucidating viral pathogenesis but also for the development of
effective prevention strategies.
DC-SIGN is one of the best-studied C-type lectin receptors
expressed on DCs, and its involvement in the capture and transfer
of HIV-1 has been intensively investigated (Arrighi et al., 2004;
Geijtenbeek et al., 2000a). DC-SIGN has also been suggested to
mediate the infection of DCs by Dengue virus and West Nile virus
(Davis et al., 2006; Miller et al., 2008; Navarro-Sanchez et al.,
2003). More recently, Shimojima et al. (2014) reported that ectopic
expression of DC-SIGN resulted in a moderately enhanced JEV
infection in a lymphoid cell line Daudi cells. However, how DC-
SIGN promotes JEV infection has yet to be deﬁned. More impor-
tantly, whether DC-SIGN mediates JEV infection of primary DCsFig. 1. DC-SIGN mediates JEV infection of DCs. (A) JEV replication in DCs. Monocyte-de
different periods of time. The intracellular expression of viral NS1 protein was detected
RNA levels in JEV-infected DCs. JEV-infected DCs (MOI of 10) were harvested on the in
quantify JEV RNA by real-time PCR. Data are expressed as JEV RNA levels relative to those
of three independent experiments. (C) Production of progeny virions from DCs. Superna
points and tittered in BHK-21 cells. Data shown are mean7SD of three independent e
infected with JEV (MOI of 1) in the presence of the anti-DC-SIGN mAb161 or an isotype
3 days later. Data shown are mean7SD of three independent experiments. ** po0.01.that endogenously expressing DC-SIGN remains to be fully
addressed.
In this study, we have demonstrated that DC-SIGN functions as
an attachment factor to facilitate JEV infection of DCs and trans-
fectants. DCs or DC-SIGN-expressing cells capture JEV via the
interaction between DC-SIGN and the high-mannose N-linked
glycan at N154 of JEV E glycoprotein, which could be blocked by
DC-SIGN-speciﬁc neutralizing antibodies or inhibitors. Binding of
JEV to DC-SIGN leads to rapid and effective virus internalization in
a DC-SIGN endocytic activity-independent manner. Our ﬁndings
suggest that DC-SIGN acts as an important JEV attachment factor
that may facilitate subsequent interaction of viral particles with an
as yet unidentiﬁed cellular receptor which leads to JEV entry
into DCs.Results
DCs support productive JEV infection
Considering the potential signiﬁcance of DCs in initiating ﬂa-
vivirus infection (Barba-Spaeth et al., 2005; Davis et al., 2006;
Jessie et al., 2004; Lozach et al., 2005), we generated primary DCs
from human peripheral blood mononuclear cells (PBMCs) and
investigated whether these cells could support JEV infection. DCs
were exposed to different amounts of JEV (MOI of 0.001, 0.1 andrived DCs were infected with JEV at different MOIs for 18 h or at a MOI of 10 for
by western blotting. One representative experiment out of three is shown. (B) Viral
dicated hours post infection (h.p.i.) and the total RNA was extracted and used to
of uninfected controls and normalized to GAPDH levels. Data shown are mean7SD
tants of cells infected with JEV (MOI of 0.1 and 10) were harvested at different time
xperiments. (D) Neutralization of DC-SIGN reduces JEV infection in DCs. DCs were
control IgG2b (20 μg/ml). Infection was quantiﬁed by titration of virus production
ns, not signiﬁcant.
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sion of NS1 was determined. Flavivirus NS1 protein is a non-
structural glycoprotein that is not incorporated into virion but only
produced in infected cells. As shown in Fig. 1A, newly synthesized
JEV NS1 was observed in JEV-pulsed DCs, indicating that DCs are
susceptible to JEV infection. Viral RNA synthesis increased over
time and peaked at 48 h post-infection (Fig. 1B), implying that the
level of viral RNA was associated with viral replication rather than
the amount of input viral particles. Titration of cell-free super-
natants, collected from challenged DCs, showed that a large
amount of infectious JEV progenies was released within 72 h post-
infection (Fig. 1C). Nevertheless, despite a productive JEV infection
in DCs, the yield of infectious JEV particles from DCs was much
lower than that from other JEV susceptible cell lines (Fig. S1A),
reﬂecting the complexity of JEV infection in primary cells.
DC-SIGN mediates JEV infection
DC-SIGN is highly expressed on DCs (Geijtenbeek et al., 2000b)
and involved in the attachment of several viruses to DCs including
HIV-1 (Pohlmann et al., 2001), Ebola (Alvarez et al., 2002) and
Dengue virus (Lozach et al., 2005; Navarro-Sanchez et al., 2003).
To examine the role of DC-SIGN in JEV infection of DCs, we ﬁrst
conﬁrmed the surface expression of DC-SIGN on DCs (Fig. S1B).
DCs were then pulsed with JEV in the presence of a neutralizing
monoclonal Ab (mAb161; clone 120507) against the carbohydrate
recognition domain (CRD) of DC-SIGN. We found that mAb161
inhibited JEV infection in a dose-dependent manner (Fig. S1C), and
the inhibition peaked at a concentration of 25 mg/ml (50–60% of
inhibition) (Fig. 1D; Fig. S1C), indicating that DC-SIGN plays a
speciﬁc role in JEV infection of DCs. Another neutralizing antibody
(clone 120526) against DC-SIGN CRD demonstrated a similar
inhibitory effect as did mAb161, whereas the antibody H200,Fig. 2. Ectopic expression of DC-SIGN enhances JEV infection. (A) JEV replication in R
expression of viral E glycoprotein was detected 36 h later by western blotting. One repre
Raji and Raji-DC-SIGN cells. Supernatants of cells infected with JEV (MOI of 0.1) were
mean7SD of three independent experiments. (C) JEV replication in cells transiently expr
infected with JEV (MOI of 0.5) and cultured for 48 or 72 h. The intracellular expression of
of three is shown. (D) Inhibition of DC-SIGN decreases JEV infection in Raji-DC-SIGN cel
(20 μg/ml) or EDTA (2.5 mM). Infection was determined by titration of virus productionwhich targets the neck region of DC-SIGN, had no effect on JEV
infection (Fig. S1D).
JEV can infect various types of primary cells and immortalized
cell lines, making it difﬁcult to ﬁnd non-permissive cells for the
study of potential viral receptors. We initially performed experi-
ments to assess the permissiveness of different cell lines to JEV.
After exposure to the same amount of JEV under the same con-
ditions, the lowest level of bound viral particles was detected in
Raji cells among several tested cell lines (Fig. S1E), suggesting that
Raji cell line is substantially less susceptible to JEV infection.
Therefore, Raji cells were used as a semi-permissive cellular model
for subsequent experiments. The capacity of DC-SIGN to promote
infection was conﬁrmed using Raji cells stably expressing DC-SIGN
(Raji-DC-SIGN) (Fig. S1F). Raji or Raji-DC-SIGN cells were infected
with JEV at different MOIs and the infection efﬁciency was
determined 36 h post infection (h.p.i.) by western blotting analysis
of JEV E protein. As expected, parental Raji cells were not infected
with JEV at a MOI of 0.02 or less, and only moderately infected
with JEV at a higher MOI of 0.1 (Fig. 2A). In contrast, when DC-
SIGN was expressed, the intracellular expression of E glycoprotein
and the production of progeny viruses were considerably elevated
(Fig. 2A and B). Similarly, infection of HEK-293T and ME180 cells
with JEV was also increased when DC-SIGN was expressed
(Fig. 2C). To further conﬁrm DC-SIGN-mediated infection, we
performed experiments in the presence of EDTA or mannan. EDTA
inhibits DC-SIGN by extracting the bound calcium, while mannan
is a competitor of insect-derived glycans. As shown in Fig. 2D, JEV
infection was signiﬁcantly reduced in Raji-DC-SIGN cells in the
presence of EDTA or mannan.
DC-SIGN enhances JEV binding to cells
We subsequently used ﬂuorescently labeled JEV particles (JEV-
AF488 and JEV-AF647) to determine whether DC-SIGN enhancedaji and Raji-DC-SIGN cells. Cells were infected with JEV at various MOIs, and the
sentative experiment out of three is shown. (B) Production of progeny virions from
harvested at different time points and tittered in BHK-21 cells. Data shown are
essing DC-SIGN. HEK-293T or ME180 cells transfected with DC-SIGN for 2 days were
viral proteins was detected by western blotting. One representative experiment out
ls. Raji-DC-SIGN cells were infected with JEV (MOI of 1) in the presence of mannan
3 days later. Data shown are mean7SD of three independent experiments.
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AF647 in DC-SIGN-expressing cells was similar to that of unlabeled
JEV (Fig. S1G), indicating that such labeling approach was unlikely
to compromise JEV infectivity. Raji and Raji-DC-SIGN cells were
exposed to various amounts of JEV-AF488, and then virus-bound
cells were determined by FACS analysis. More JEV-AFF488-positive
cells and higher corresponding mean ﬂuorescence intensity (MFI)
were observed in Raji-DC-SIGN than those in parental Raji cells
under the same conditions (Fig. 3A). Moreover, JEV binding to Raji-
DC-SIGN cells was suppressed by pretreatment with the inhibitors
described above (80% reduction with mAb161 or EDTA and
40% with mannan in MFI) (Fig. 3B), suggesting the speciﬁcity of
DC-SIGN-mediated JEV binding.
We further used DCs to examine the role of DC-SIGN in med-
iating JEV binding. DCs transfected with DC-SIGN-speciﬁc siRNA or
control siRNA for 2 days were incubated with JEV-AF488, stained
with anti-DC-SIGN Ab and subjected to FACS analysis. The number
of virus-bound cells and MFI decreased when DC-SIGN was
knocked down (Fig. 3C). In addition, JEV-AF488 particles could be
visualized as single spots by confocal microscopy, and the virus
binding on DCs was severely compromised when DC-SIGN was
knocked down by DC-SIGN siRNA or neutralized by anti-DC-SIGN
mAb161 (Fig. 3D). These results suggest an important role of DC-
SIGN in DC-mediated JEV binding.
High-mannose N-linked glycan at N154 of E glycoprotein is respon-
sible for DC-SIGN-mediated JEV binding
To assess the interaction between DC-SIGN and JEV, CHO cells
transiently expressing DC-SIGN were ﬁrst pulsed with JEV and
then ﬁxed and immunostained with anti-JEV E and anti-DC-SIGN
antibodies before confocal microscopy. Our results showed that
DC-SIGN, in the absence of JEV infection, revealed a punctate
expression pattern and was evenly distributed all over the cell
surface (Fig. 4A, horizontal middle panel). JEV binding caused
enhanced co-clustering of DC-SIGN (red) and virus particles
(green) in a large and patchy conﬁguration (yellow), which pro-
truded from the cell surface, indicating that JEV binding may result
in DC-SIGN redistribution (Fig. 4A, lower panel). Moreover, virus
binding was considerably increased on CHO-DC-SIGN cells than
that on parental CHO cells (Fig. 3A, top and lower panels).
It has been well documented that DC-SIGN binds high mannose
N-linked glycans through its C-terminal carbohydrate recognition
domain (CRD) (van Kooyk and Geijtenbeek, 2003). We therefore
analyzed the glycosylation patterns of JEV E glycoprotein. E gly-
coprotein was treated with endoglycosidase H (Endo H) or Pep-
tide: N-glycosidase F (PNGase F) before SDS-PAGE and western
blotting analyses. Endo H only digests high mannose-type glycans,
while PNGase F cleaves both high mannose- and complex-type
glycans. In our study, treatment with Endo H or PNGase F had the
same effect on the migration of E protein (Fig. 4B), suggesting that
N-linked glycans on E glycoprotein are highly likely to be high
mannose-type. We next examined the potential N-linked glyco-
sylation sites on E protein by analyzing sequence motifs N-X-S/T
and N-X-C. The JEV E glycoprotein possesses two potential N-
linked glycosylation sites, N103-G104-C105 and N154-T155-S156.
After Endo H or PNGase F treatment, E protein with deglycosyla-
tion at N154 (E-N154Q) but not at N103 (E-N103Q) revealed the
same migration pattern (Fig. 4B), suggesting a single high-
mannose N-linked glycan at N154. In the cell–cell fusion system,
the fusion between deglycosylation mutant N154 (E-S154A)-
expressing effector cells and DC-SIGN-expressing target cells was
severely impaired. On the contrary, the glycan-retained mutant E-
S156T showed similar fusion activity as the wild-type E protein
(Fig. S2A and B). In addition, the fusion efﬁciency was decreased by
inhibitors that targeting the interaction between DC-SIGN andhigh-mannose glycans (Fig. S2C). These results collectively
demonstrate that high-mannose N-linked glycan at N154 is
important in mediating the interaction between JEV E protein and
DC-SIGN.
To further understand the importance of high-mannose N-
linked glycan in DC-SIGN-JEV interaction, JEV produced in C6/36
cells was treated with Endo H under reducing conditions before
exposed to Raji-DC-SIGN cells. Our results revealed that, although
glycan removal was incomplete (Fig. S2D), Endo H treatment
severely compromised the binding of C6/36 cell-derived JEV to
Raji-DC-SIGN (Fig. 4D and E) but did not signiﬁcantly affect its
infectivity in the highly permissive BHK-21 cells (Fig. 4C), implying
a close association of the high-mannose N-linked glycan on E
protein with DC-SIGN binding. This was further conﬁrmed by
using an infectious JEV clone bearing a deglycosylation mutation
at N154 (JEV-N154A) (Liu et al., 2015). Compared to wild type JEV,
JEV-N154A showed compromised infection in Raji-DC-SIGN cells
and was not sensitive to neutralizing antibody against DC-SIGN
(Fig. S2E).
JEV internalization is independent of DC-SIGN endocytic activity
The cytosolic tail of DC-SIGN carries several sequence motifs
that are believed to be important for signaling, endocytosis and
intracellular trafﬁcking. The classical LL motif present in the
cytosolic tail has been shown to be critical for DC-SIGN endocy-
tosis (Engering et al., 2002; Figdor et al., 2002; van Kooyk and
Geijtenbeek, 2003). To test whether DC-SIGN facilitates JEV inter-
nalization, we generated DC-SIGN LL/AA mutant with the LL
sequence being substituted with two alanines. Following detection
of intracellular and cell-surface expression, we veriﬁed that DC-
SIGN LL/AA was expressed at the same level as the wild type DC-
SIGN (Fig. 5A and B).
To conﬁrm that DC-SIGN LL/AA was devoid of endocytic activ-
ity, we performed Ab-mediated DC-SIGN endocytosis in HeLa cells.
Cells were incubated with the anti-DC-SIGN mAb161 for 1 h at
4 °C, washed extensively and then shifted to 37 °C to initiate DC-
SIGN internalization. At 4 °C, DC-SIGN and DC-SIGN LL/AA were
mainly detected at the cell surface. When at 37 °C, a dramatic
redistribution of staining in DC-SIGN was observed, indicating that
DC-SIGN was efﬁciently internalized in HeLa cells upon mAb161
binding (Fig. 5C, upper panel). In contrast, the majority of DC-SIGN
LL/AA remained mainly on the surface of HeLa cells after mAb161
binding (Fig. 5C, lower panel). These data indicate that DC-SIGN
LL/AA can efﬁciently bind antigens but is incapable of
internalization.
Subsequently, HeLa cells expressing wild type DC-SIGN or DC-
SIGN LL/AA were incubated with JEV-AF647 on ice. After extensive
washes with cold PBS, cells were rapidly shifted to 37 °C for the
times indicated to allow internalization. Cells were then mock
treated or treated with trypsin to remove the cell-surface bound
viruses. FACS data showed that, without trypsin treatment, virus
binding was equally efﬁcient in DC-SIGN LL/AA and DC-SIGN
expressing cells (Fig. 5D), indicating that the endocytosis motif
of DC-SIGN is dispensable for antigen binding. Without shifting to
37 °C, trypsin treatment resulted in an abrogation of JEV-AF647
binding. After incubation for 5 min at 37 °C, approximately 20% of
JEV-AF647 particles was protected from trypsin treatment. The
internalization of JEV-AF647 increased over time, and most parti-
cles were internalized within 30 min. Of importance, there was no
difference in JEV internalization between DC-SIGN and DC-SIGNA
LL/AA (Fig. 5D). Interestingly, the kinetic of virus uptake into DCs
appeared to be slightly faster with most particles being inter-
nalized within 15 min (Fig. S3).
To further verify that the endocytic activity of DC-SIGN is not
required for JEV internalization, we examined JEV-pulsed DCs by
P. Wang et al. / Virology 488 (2016) 108–119112
P. Wang et al. / Virology 488 (2016) 108–119 113ﬂuorescence confocal microscopy. DCs were pulsed with JEV-
AF647 on ice and then shifted to 37 °C for indicated times. Cells
were then ﬁxed, permeabilized and stained for DC-SIGN, early
endosomal marker EEA-1 or lysosomal/late endosomal marker
LAMP-1. After a short incubation of 5–15 min at 37 °C, colocaliza-
tion of JEV-AF647 was observed with EEA-1-positive early endo-
somes but not with DC-SIGN (which was mainly distributed on the
cell surface) (Fig. 5E), suggesting that unknown factors rather than
DC-SIGN mediated internalization and intracellular routing of JEV.
Of interest, even after 2 h, JEV-AF647 was still present primarily in
EEA-1-positive early endosomes instead of LAMP-1-positive vesi-
cles (Fig. 5F). These results together indicate that JEV entry into
DC-SIGN-expressing cells is independent of the endocytic activity
of DC-SIGN.Discussion
Dendritic cells (DCs) in the skin and mucosal tissues form a
ﬁrst-line defense against viruses and other pathogens (Knight and
Patterson, 1997). In this study, we demonstrate that DCs support
JEV productive infection. DC-SIGN-mediated JEV binding is
required for JEV infection of DCs and transfectants. Moreover,
binding of JEV to DC-SIGN leads to rapid and effective virus
internalization independent of DC-SIGN endocytic activity, indi-
cating that DC-SIGN functions as an attachment factor rather than
an entry receptor for JEV infection. In addition, the high-mannose
N-linked glycan at N154 of E glycoprotein is essential for JEV
binding to DC-SIGN.
Attachment factors that promote virus binding to target cells
are not essential for viral entry but increase the chance of inter-
actions between viral glycoproteins and cellular entry receptor(s),
and consequently enhance viral infection. DC-SIGN is one of the
most extensively characterized viral attachment factor abundantly
expressed on DCs, and has been shown to enhance the capture of a
number of viral pathogens, including HIV-1, Ebola virus, cytome-
galovirus and Dengue virus (Alvarez et al., 2002; Geijtenbeek et al.,
2000a; Halary et al., 2002; Navarro-Sanchez et al., 2003). In this
study, we have demonstrated that DC-SIGN augmented JEV bind-
ing to primary DCs which was signiﬁcantly impaired but not
totally blocked when DC-SIGN was neutralized or knocked down,
implying that DC-SIGN likely plays an important but not exclusive
role in mediating JEV infection of DCs. Moreover, JEV E protein
bound to DC-SIGN in a Ca2þ-dependent manner and the binding
could be inhibited by mannan, indicating a carbohydrate-C type
lectin speciﬁc interaction. Treatment of JEV particles with Endo H
signiﬁcantly reduced JEV infection of DC-SIGN-expressing cells,
suggesting that the high mannose glycans present on the surface
of mosquito-derived virions are essential for the interaction of JEV
with DC-SIGN. To this end, a single high-mannose N-linked gly-
cosylation site at N154 was identiﬁed in JEV E protein, which was
sensitive to Endo H treatment and carbohydrate-binding agent CV-
N, and this glycan accounted for the binding capability of JEV to
DC-SIGN. The signiﬁcance of glycosylation at N154 in DC-SIGNFig. 3. DC-SIGN promotes JEV binding to cells. (A) Binding of JEV-AF488 to Raji and Raji-DC-SIG
or Raji-DC-SIGN cells for 1 h on ice and washed extensively before ﬁxation and FACS analysis.
from three independent experiments are shown as mean7SD (right). (B) Inhibition of DC-SIG
with anti-DC-SIGN antibody (mAb161, 25 μg/ml), mannan (20 μg/ml) and EDTA (2.5 mM), re
representative experiment out of three is shown (left). TheMFI values of JEV-AF488 from three i
the absence of inhibitors was set to 100%. (C) DC-SIGN knockdown reduces JEV-AF488 binding
with JEV-AF488 (MOI of 10). DCs without transfection were used as the control. One representa
normalized to that without transfection. Data shown are mean7SD of three independent expe
DCs. JEV-AF488 bound to DCs transfected with DC-SIGN siRNA or in the presence of anti-DC-S
cell-associated virus particles (JEV-AF488) seen in one focal plane. Nuclei were stained with Hoe
mAb161 (n¼37), isotype control (n¼39), control siRNA (n¼38) or DC-SIGN siRNA (n¼45), wusage was further conﬁrmed in the context of viral infection using
an infectious JEV clone carrying N154 deglycosylation mutation.
These results were consistent with other studies that DC-SIGN
mainly recognizes high-mannose N-linked glycans on viral
envelope glycoproteins (Guo et al., 2004) and deletion of N-gly-
cosylation sites on E glycoprotein of Dengue virus resulted in
compromised infectivity in DCs and DC-SIGN-expressing cell lines
(Alen et al., 2012).
By analogy to other ﬂaviviruses, JEV is supposed to gain entry
into target cells via receptor-mediated endocytosis (Pierson and
Kielian, 2013). Indeed, we found that binding of JEV to DC-SIGN
triggered a rapid and efﬁcient internalization of viral particles,
suggesting the involvement of endocytic pathway in DC-SIGN-
mediated JEV infection. However, these results did not distinguish
whether DC-SIGN acts as cell surface attachment factor or as an
authentic entry receptor that mediates virus internalization. DC-
SIGN contains three motifs in its cytoplasmic tail that are believed
to be involved in internalization or endocytic trafﬁcking, including
two classically deﬁned putative internalization motifs, a dileucine
motif (LL) and a tyrosine-based motif (YSKL), and a triacidic (EEE)
cluster (Engering et al., 2002; van Kooyk and Geijtenbeek, 2003).
Substitution of the LL motif with alanines abolished DC-SIGN
endocytosis induced by mAb161, indicating that LL motif is
essential to mediate DC-SIGN endocytosis. We observed that cells
expressing endocytosis-defective DC-SIGN mediated JEV binding
and entry with an efﬁciency similar to that of cells expressing wild
type DC-SIGN, and most of JEV particles were no longer coloca-
lized with DC-SIGN after viral internalization, indicating that JEV
entry into DC-SIGN-expressing cells is not dependent on the DC-
SIGN endocytic activity. Our ﬁndings are in agreement with an
earlier study suggesting that DC-SIGN-mediated enhancement of
Dengue virus infection is independent of DC-SIGN internalization
signals (Lozach et al., 2005). Our data together suggest that DC-
SIGN plays an important if not exclusive role as a cell surface
attachment factor for JEV. Although JEV internalization could be
independent of DC-SIGN endocytic activity in HeLa cells, these
results do not rule out the possibility that a proportion of JEV
entered DCs directly through DC-SIGN endocytosis or JEV bene-
ﬁted from the endocytic activity of DC-SIGN for a rapid inter-
nalization. It is also probable that DC-SIGN-bound JEV particles
could be internalized by alternative mechanisms as described
previously for DC-SIGN-mediated entry of Mycobacterium tuber-
culosis (Geijtenbeek et al., 2003; Tailleux et al., 2003). Collectively,
our ﬁndings imply the existence of a speciﬁc receptor rather than
DC-SIGN required for JEV internalization. Several molecules such
as HSP70, heparan sulfate and low-density lipoprotein receptors
have been proposed to participate in JEV entry into target cells but
their role as authentic cellular receptors for JEV is doubted (Chien
et al., 2008; Das et al., 2009; Liu et al., 2004; Zhu et al., 2012). We
propose that DC-SIGN as the attachment factor captures virus on
the cell surface and cooperates with an unidentiﬁed cellular entry
receptor to permit infection of skin DCs during the mosquito's
blood meal.N cells. Various amounts of ﬂuorescent JEV particles (JEV-AF488) were incubated with Raji
One representative experiment out of three is shown (left). The MFI values of JEV-AF488
N decreases JEV-AF48 binding to Raji-DC-SIGN cells. Raji-DC-SIGN cells were pre-treated
spectively, before pulsed with JEV-AF488 on ice in the presence of the inhibitors. One
ndependent experiments are shown asmean7SD (right). Binding to Raji-DC-SIGN cells in
to DCs. DCs were transfected with DC-SIGN siRNA or control siRNA for 36 h before pulsed
tive experiment out of three is shown (left). The MFI of bound viruses was measured and
riments (right). (D) DC-SIGN neutralizing antibody mAb161 reduces JEV-AF488 binding to
IGN mAb161 (25 μg/ml) on ice before imaging by confocal microscopy. Green spots were
chst (blue). Bound particles per DC in the absence (n¼41) or presence of the anti-DC-SIGN
ere counted in ten independent ﬁelds. ** po0.01. ns, not signiﬁcant.)
P. Wang et al. / Virology 488 (2016) 108–119114Flaviviruses are internalized via pre-formed clathrin-coated
pits that bud into the cytosol and deliver their cargo to endocytic
pathways, followed by degradation of viral particles and leaking of
viral RNA (Pierson and Kielian, 2013). Studies on Dengue and West
Nile viruses have demonstrated that the virus moves from early
endosomes to late endosomes before viral RNA is released (Chu et
al., 2006; Chu and Ng, 2004a; Mosso et al., 2008; van der Schaar et
al., 2008). In contrast, Krishnan et al's study based on RNA inter-
ference showed that the uncoating of Dengue and West Nile
viruses occurs at the level of early endosomes (Krishnan et al.,
2007). A study on JEV suggested that the infection process in both
ﬁbroblasts and neuronal cells requires acid-dependent fusion atFig. 4. High-mannose N-linked glycan at N154 of E glycoprotein is responsible for th
expressing cells. DC-SIGN transfectants (CHO-DC-SIGN) and parental CHO cells were incu
Cells were ﬁxed and stained for E glycoprotein (green) and DC-SIGN (red) followed by an
confocal microscope. Arrows denote the overlapping domains of expression (yellow). As
above. Scale bar represents 11 μm. (B) Glycosylation pattern of E glycoprotein. Wild type
under reducing conditions and analyzed by western blotting with polyclonal Abs agains
under nondenaturing conditions has no effect on JEV infectivity. C6/36-derived JEV was
infectivity in BHK-21 cells. Data shown are mean7SD of three independent experimen
Endo H treatment reduces the capability of JEV in infecting Raji-DC-SIGN cells. Raji or Ra
the expression of viral proteins was detected 2 d later by western blotting (D). One repre
and tittered in BHK-21 cells. Data shown are mean7SD of three independent experimethe level of early endosomes (Kalia et al., 2013). In our study, we
found that the number of JEV particles in early endosomes was not
signiﬁcantly decreased throughout the experiment, implying that
JEV uncoating may not occurs in early endosomes of DCs. It is
likely that the endocytic route of JEV is ligand and cell type
dependent.
Tracking studies of ﬂuorescently labeled particles in live cells
indicate that cargo delivered from cell surface such as transferrin
or epidermal growth factor typically reaches early endosomes in
less than 2 min after internalization, late endosomes in the peri-
nuclear region after 10–12 min, and the lysosomes within 30–
60 min (Grifﬁths et al., 1989; Lakadamyali et al., 2006; Mercer ande binding of JEV to DC-SIGN. (A) Confocal microscopy of JEV bound to DC-SIGN-
bated with JEV (MOI of 5), respectively, for 2 h on ice and then washed extensively.
alyses under ﬂuorescence (488/640 nm) and differential interference contrast (DIC)
a control, CHO-DC-SIGN cells without JEV incubation were performed as described
and mutated E glycoproteins were digested with PNGase F or Endo H (2000 units)
t JEV E glycoprotein. Arrows denote protein bands of interest. (C) Endo H treatment
treated with Endo H (5000 units) under nondenaturing conditions and assessed for
ts with each condition performed in duplicate. ** po0.01. ns, not signiﬁcant. (D,E)
ji-DC-SIGN cells were infected with Endo H-pre-treated JEV as described in (C), and
sentative experiment out of three is shown. The supernatants of cells were collected
nts. ** po0.01. ns, not signiﬁcant.
Fig. 5. JEV internalization does not require DC-SIGN endocytosis. (A,B) HeLa cells were transfected with expressing constructs encoding DC-SIGN or DC-SIGN LL/AA followed by
analyses of intracellular expression by western blot (A) or surface expression by FACS (B). (C) Subcellular localization of DC-SIGN and DC-SIGN LL/AA in HeLa cells. Anti-DC-SIGN
mAb161 was incubated with HeLa cells expressing DC-SIGN or DC-SIGN LL/AA for 1 h at 4 °C. Cells were washed extensively to remove unbound antibody and incubated for 30 min at
4 or 37 °C. mAb161-bound DC-SIGN was detected with a FITC-conjugated secondary Ab. Cell surface and intracellular localization of DC-SIGN was examined by confocal microscopy.
Representative images from three independent experiments are shown. (D) JEV-AF647 internalization into HeLa-DC-SIGN or HeLa-DC-SIGN LL/AA cells. HeLa cells expressing DC-SIGN
or DC-SIGN LL/AAwere incubated with JEV-AF647 (MOI of 10) on ice, washed, and shifted to 37 °C for the times indicated. Cells were then treated with trypsin or mock treated, ﬁxed,
and washed extensively followed by FACS analysis. One representative experiment out of three is shown (left). The MFI values of internalized JEV-AF647 from three independent
experiments are shown as mean7SD (right). Binding of JEV-A647 to DC-SIGN-expressing HeLa cells without shifting and trypsin treatment was set to 100%. (E,F) JEV-AF647
internalization into DCs. DCs were incubated with JEV-AF647 (MOI of 20) on ice, washed, and shifted to 37 °C for the times indicated. Cells were then ﬁxed, permeabilized and stained
for DC-SIGN, early endosome-speciﬁc marker EEA-1 or late endosome-speciﬁc marker LAMP-1.
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P. Wang et al. / Virology 488 (2016) 108–119116Helenius, 2008). Studies on Dengue and West Nile viruses showed
that the virus could be observed in numerous of early endosomes
at 2–5 min after internalization, late endosomes at 10–15 min, and
predominantly in lysosomes within 20–60 min (Acosta et al., 2012;
Chu and Ng, 2004a; van der Schaar et al., 2008, 2007; Zaitseva et
al., 2010). The trafﬁcking process of Dengue and West Nile viruses
along the endocytic pathway occurs rapidly and is consistent with
the speed of typical trafﬁcking of cellular ligands. In consistence,
our study showed that binding of JEV to DC-SIGN induced rapid
and efﬁcient internalization of the viruses into DCs. At 5 min after
cells were warmed to 37 °C, virus particles were found mainly in
EEA-1-positive early endosomes. However, colocalization
remained high for JEV and early endosomes by 2 h, indicating that
some virus particles remained in early endosomes of DCs for a
longer period of time. Kwon et al. demonstrated that the vast of
internalized HIV-1 virions into DCs do not enter late endosomes or
lysosomes but instead in the early endosomes with stable and
retaining infectivity for days (Geijtenbeek et al., 2000a). Another
study has shown that Hepatitis C virus targets DC-SIGN to early
endosomes of DCs, where the virus particles are protected from
degradation for a long period (424 h) (Ludwig et al., 2004).
Although we did not observe a colocalization of JEV with DC-SIGN
in early endosomes, we cannot completely rule out the possibility
that intracellular trafﬁcking of JEV particles may be dependent on
the initial virion uptake. Moreover, future studies are warranted to
determine whether a delayed degradation of JEV in DCs is asso-
ciated with viral immune evasion or/and transmission.
In conclusion, we have demonstrated that DC-SIGN functions as
an attachment factor to promote JEV binding to DCs via its high
afﬁnity for high-mannose glycan on E glycoprotein, while ectopic
expression of DC-SIGN enhances JEV infection in cell lines. Binding
to DC-SIGN triggers rapid JEV internalization into cells. However,
JEV internalization appears to be independent of DC-SIGN endo-
cytic activity with virions persistent in the early endosomes of DCs
for a long period. Our ﬁndings highlight the potential importance
of DC-SIGN in the early stages of JEV infection, although the sig-
niﬁcance in vivo remains to be further elucidated in future animal
or clinical studies. Further understanding the roles of DC-SIGN in
JEV infection may have important implications for the develop-
ment of intervention strategies.Materials and methods
Ethic statement
All protocols involving human blood samples were reviewed and
approved by the Local Research Ethics Committee. Informed written
consents from the human subjects were obtained in this study. Animal
experiments were approved by the Institutional Animal Care and Use
Committee (Hubei Laboratory Animal Science Association, Wuhan,
China, Approval ID: S03409100L and S03409110D) and performed in
accordance with the guidelines of Hubei Laboratory Animal Science
Association.
Cells and viruses
Japanese quail ﬁbrosarcoma cells (QT6), Chinese hamster ovary
(CHO) cells, human cervical carcinoma cells (ME180), baby ham-
ster kidney cell line (BHK-21) and human embryonic kidney 293T
cells (HEK-293T) were purchased from the American Type Culture
Collection (ATCC). All cells were grown in Dulbecco's Modiﬁed
Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal
bovine serum (FBS; Invitrogen), 100 U/ml penicillin–streptomycin,
and 2 mM L-glutamine. Human Burkitt's lymphoma cell line Raji
was purchased from ATCC and cultured in RPMI-1640 medium(Invitrogen) supplemented with 10% FBS, 100 U/ml penicillin–
streptomycin, 2 mM L-glutamine. Stable cell line Raji-DC-SIGN was
described previously (Du et al., 2012) and maintained in RPMI-
1640 supplemented with 10% FBS, 500 mg/ml G418, 100 U/ml
penicillin–streptomycin, and 2 mM L-glutamine. Aedes albopictus
C6/36 cells (ATCC) were grown in EMEM (ATCC) supplemented
with 10% FBS and maintained at 28 °C in the presence of 5% CO2.
All other cell lines were grown at 37 °C in the presence of 5% CO2.
Primary DCs were obtained as described previously (Hu et al.,
2004; Jin et al., 2014). In brief, human peripheral blood mono-
nuclear cells (PBMCs) were isolated from blood samples collected
from healthy adult volunteers by the standard Ficoll–Paque method.
For preparation of DCs, monocytes were ﬁrst isolated from PBMCs
by negative selection using human Monocyte Isolation kit II (Mil-
tenyi Biotec). Puriﬁed monocytes were then differentiated into DCs
in the presence of IL-4 (500 U/ml) and granulocyte-macrophage
colony-stimulating factor (GM-CSF, 800 U/ml). DCs were harvested
at day 6, analyzed by FACS and used in subsequent assays.
The JEV strain AT31 (Zu et al., 2014) was propagated in C6/36
cells and tittered in BHK-21 cells. JEV infectious clone carrying a
deglycosylation mutation at N154 (JEV-N154A) was described
previously (Liu et al., 2015). For JEV deglycosylation assay and
ﬂuorescent staining, viruses were concentrated and puriﬁed by
ultracentrifugation. Brieﬂy, 25 ml of virus-containing medium
(cleared by centrifugation and ﬁltration) was overlaid on 5 ml of
25% sucrose in Beckman conical tubes and spun at 25,000 rpm for
2 h at 4 °C in Beckman SW28 swingle bucket rotor (Beckman
Coulter). The resulting pellet was dissolved in 100 μl/tube of PBS
without calcium or magnesium (Invitrogen) for 2 h at 4 °C. Ali-
quots were stored at 80 °C or proceeded to puriﬁcation. For
puriﬁcation of JEV, concentrated viruses were overlaid on a con-
tinuous sucrose gradient (20–55% w/w in H2O) and spun at
35,000 rpm for 2 h at 4 °C in Beckman SW55 swingle bucket rotor
(Beckman Coulter). Labeling of JEV with Alexa Fluors 488 or Alexa
Fluors 647 Carboxylic Acid (Invitrogen) was performed in HEPES
(20 mM) according to the manufacturer's instructions. Labeled
viruses were separated from free dye by using a gel ﬁltration
column and subsequently banded on a sucrose step gradient as
described above. Proper labeling was veriﬁed by SDS-PAGE, and
the infectivity was monitored by plaque assays. The labeled JEV
was designated JEV-AF488 or JEV-AF647.
Antibodies, plasmids, siRNAs and chemicals
Mouse anti-DC-SIGN neutralizing mAb mAb161 (clone 120507),
mouse anti-DC-SIGN phycoerythrin (PE)-conjugated mAb (mAb507)
and corresponding isotype control antibodies were purchased from
R&D Systems. Mouse anti-DC-SIGN neutralizing mAb clone 120526
was from the AIDS Research and Reference Reagent Program of NIH.
Rabbit anti-EEA-1 mAb and rabbit anti-LAMP-1 mAbwere purchased
from Cell Signaling Technology (Beverly, MA). Mouse anti-DC-SIGN
mAb (sc-65740), rabbit anti-DC-SIGN polyclonal antibody H200,
mouse anti-β-actin and horseradish peroxidase (HRP) conjugated
goat-anti-mouse antibodies were from Santa Cruz. Anti-Japanese
encephalitis virus NS1 glycoprotein antibody (ab41651) was from
Abcam. Alexa Fluors 488-conjugate goat anti-mouse IgG and Alexa
Fluors 568-conjugate goat anti-rabbit IgG were purchased from
Invitrogen Life Technologies. Mouse polyclonal antibody against the
domain III of JEV E glycoprotein was generated by immunization of
BALB/c mice (BHK ltd. Beijing) with JEV E DIII protein (Zu et al., 2014).
Brieﬂy, mice were ﬁrst immunized subcutaneously with 200 μg of
JEV E DIII protein in Freund's complete adjuvant followed by two
boost immunizations with the same amount of antigen in Freund's
incomplete adjuvant at 3-week intervals. Two weeks after the ﬁnal
immunization, blood samples were collected and sera were pooled
and puriﬁed with protein A/G (Invitrogen).
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maturation (Li et al., 2008; Lorenz et al., 2002), the DNA sequence
containing full length PrM and the gene which encodes functional
E protein was ampliﬁed from JEV infectious cDNA (Li et al., 2014)
and cloned into pcDNA3.1 (þ), designated wild type E. Deglyco-
sylation E mutants E-N154Q, E-N103Q, E-S156A and glycan-
retained mutant E-S156T were generated by site-direct mutagen-
esis (Aligent Technology) according to the manufacturer's
instructions. Cyanovirin (CV-N) (Hu et al., 2010) and construct
expressing wild type DC-SIGN (pDC-SIGN) was described pre-
viously (Du et al., 2012). DC-SIGN LL/AA, a mutant defective in
endocytosis, was generated by site-directed mutagenesis and
inserted into pcDNA3.1 vector. DC-SIGN-speciﬁc siRNA (sc-43719)
and control siRNA were from Santa Cruz and described previously
(Jin et al., 2014). EDTA and mannan were from Sigma-Aldrich.
Western blotting
Protein extracts, separated by SDS-PAGE and transferred onto
PVDF membranes, were probed with antibodies against JEV E
(1:2000), NS1 (1:1000), DC-SIGN (1:3000) and β-actin (1:2000,
Santa Cruz Biotech), respectively. Proteins of interest were detec-
ted with the HRP-conjugated goat anti-mouse IgG antibody
(1:5000, Santa Cruz Biotech) followed by the addition of the Pierce
ECL Western blotting substrate (Thermo Scientiﬁc, Rockford, IL).
Virus deglycosylation
Wild-type and mutated E glycoproteins were digested with
PNGase F (2000 U, New England Biolabs) or Endo H (2000 U, New
England Biolabs) under reducing conditions for 3 h at 37 °C
according to the manufacturer's instructions. Native deglycosy-
lated viruses were obtained under nondenaturing conditions
where samples were incubated with Endo H (5000 U) for 6 or 12 h
at 37 °C without the denaturing step and Nonidet P-40 buffer
(New England Biolabs) treatment.
E glycoprotein-mediated cell–cell fusion
The interaction between E glycoprotein and DC-SIGN was
assayed using a cell–cell fusion assay employing a luciferase
reporter gene, as described previously with modiﬁcation (Hu et al.,
2010). Brieﬂy, QT6 effector cells were ﬁrstly infected with vTF1.1, a
virus encoding T7 polymerase, for 1 h followed by transfection
with construct expressing wild type or mutated E protein. QT6
target cells were transfected with pDC-SIGN and construct
encoding luciferase under the transcriptional control of T7 pro-
moter. The effector and target cell populations were mixed at 16–
18 h post-transfection. Luciferase activity of cell lysates was
determined approximately 8 h later (Promega). In some cases,
effector cells were pre-treated with inhibitors for 30 min before
mixed with target cells.
Virus binding and infection
Cells were incubated with JEV or JEV-AF488 for 2 h on ice at
various multiplicity of infection (MOI) in binding buffer (RPMI-
1640 pH7.4 containing 0.2% FBS, 1 mM CaCl2, and 2 mM MgCl2),
followed by washes with cold PBSþ1% BSA to remove unbound
viruses. Binding was subsequently quantiﬁed by FACS or analyzed
by ﬂuorescence microscopy. For microscopy, DCs were stretched
on poly-L-lysine-coated cover slips for 1 h at 37 °C before incuba-
tion with JEV-AF488. For inhibition assay, cells were pretreated
with inhibitors for 30 min before exposure to viruses.
For virus infection assay, cells were incubated with JEV for 2 h
at 37 °C and cultured for indicated times. After incubation,intracellular expression of viral protein NS1 or E was detected by
western blotting. For inhibition assay, cells were pretreated with
inhibitors for 30 min before exposure to viruses.
DC-SIGN endocytosis assay
HeLa cells expressing wild type DC-SIGN or DC-SIGN LL/AA
(6105 cells) were seeded on 3.5 cm diameter glass bottom cul-
ture dishes (MatTek Corporation) pre-coated with poly-L-lysine.
Cells were incubated with the anti-DC-SIGN mAb161 (20 mg/ml
diluted in PBS containing 3% BSA) for 1 h at 4 °C. After three
washes with ice cold PBS to remove unbound Abs, cells were
shifted to 37 °C for 30 min to allow DC-SIGN endocytosis. Cells
were ﬁxed with 3% paraformaldehyde for 15 min, washed and
treated with PBS 0.2 M glycine for 10 min. Cells were then incu-
bated with PBS containing 0.02% saponin and 1.5% BSA for 30 min.
To visualize mAb161-bound DC-SIGN, cells were incubated with
FITC-conjugated goat anti-mouse IgG, then washed and subjected
to microscopy imaging.
JEV internalization assay
Wild type DC-SIGN or DC-SIGN LL/AA-expressing HeLa cells
were incubated in serum-free DMEM containing 1 mM CaCl2,
2 mM MgCl2, and JEV-AF647 (MOI of 10) for 1 h at 4 °C. Unbound
viruses were removed by extensive washes with serum-free
DMEM. Cells were then suspended in serum-free DMEM, and
shifted to 37 °C for various time periods. Cells were mock treated
with serum-free DMEM or treated with 0.05% trypsin (Life Tech-
nologies) for 5 min. Proteolysis was stopped by adding an equal
volume of medium containing 20% FCS. Cells were then subjected
to FACS analysis.
DCs were adhered to polylysine-treated glass slides for 45 min
in PBS at room temperature. Slides were then incubated with JEV-
AF647 (MOI of 20) for 2 h on ice, washed, and then shifted to 37 °C
for the indicated times. After incubation, cells were ﬁxed with 4%
paraformaldehyde, and permeabilized with PBS containing 0.05%
saponin and 0.2% BSA. Cells were then stained with mouse anti-
DC-SIGN mAb, rabbit anti-EEA-1 mAb or rabbit anti-LAMP-1 mAb
for 1 h on ice followed by staining with Alexa Fluors 488-
conjugate goat anti-mouse IgG or Alexa Fluors 568-conjugate
goat anti-rabbit IgG. After a ﬁnal wash, cells were subjected to
confocal analysis as described elsewhere (Jiang et al., 2014). Brieﬂy,
images were obtained by using a 60NA 1.4 oil objective (Nikon
eclipse Ti inverted microscope) on a spinning-disk confocal
microscope (UltraView VoX; PerkinElmer Life and Analytical Sci-
ences). Images were gathered under the laser of 488 nm, 561 nm,
640 nm and differential interference contrast (DIC) mode. Image
sequences were processed and analyzed with Volocity software
(PerkinElmer).
Statistical analysis
Analyses were performed with GraphPad Prism 4.00 software
(GraphPad). Values were given as the mean of triplicates7-
standard deviation (SD). Statistical analysis was performed using
the Student's t-test. A p value o0.05 was considered statistically
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